Worldwide trials are testing mesenchymal stem cells to battle graft-versus-host disease. The stem cells seem to have anti-inflammatory and immuno-modulatory abilities. "In terms of laboratory tests they have been shown to inhibit different aspects of the immune response, such as T cell responses, they inhibit cytokine production and they also inhibit dendritic cells," said one expert.

Related Summaries